Toward a molecular classification of the gliomas: Histopathology, molecular genetics, and gene expression profiling

Histology and Histopathology

Volumn 15, Issue 3, 2000, Pages 971-981

  Caskey, L S ^a   Fuller, G N ^a   Bruner, J M ^a   Yung, W K A ^a   Sawaya, R E ^a   Holland, E C ^a   Zhang, W ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

cDNA microarray; Classification; Gliomas

Indexed keywords

DNA; RNA;

BRAIN TUMOR; CELL PROLIFERATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; GLIOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; REVIEW; TUMOR CLASSIFICATION;

BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GLIOMA; HUMANS;

EID: 0033913658     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Complementary DNA sequencing: Expressed sequence tags and the human genome project
2. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q
3. Regulation of MDM2 expression by p53: Alternate promoters produce transcripts with nonidentical translation potential
4. Allelic status of chromosome 1 in neoplasms of the nervous system
5. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
6. Morphologic and molecular genetic aspects of oligodendroglial neoplasms
7. The p53 gene and its role in human brain tumors
8. Normalization and subtraction: Two approaches to facilitate gene discovery
9. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays
10. Tumors of the central nervous system
11. Histologic factors of prognostic significance in the glioblastoma multiforme
12. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme
13. Glioblastoma multiforme and anaplastic astrocytoma: Pathological criteria and prognostic implications
14. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
15. Cell cycle and proliferation markers in neuroepithelial tumors
16. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas
17. Grading of astrocytomas. A single and reproducible method
18. Use of a cDNA microarray to analyze gene expression patterns in human cancer
19. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails
20. Assessment of brain tumor proliferation potential
21. Central nervous system tumors
22. Classification and biology of brain tumors
23. Gliomas: Pathology
24. Central nervous system
25. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: A revelation by parallel gene expression profiling
26. Genetics and malignant progression of human brain tumors
27. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas
28. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV therapy
29. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors
30. Vascular smooth muscle hyperplasia underlines the formation of glomeruloid vascular structures of glioblastoma multiforme
31. Biochemical properties and biological effects of p53
32. Lack of p16INK4 retinoblastoma protein (pRb) or amplication-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines
33. Serial analysis of gene expression in non-small cell lung cancer
34. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice
35. 1 cell-cycle arrest pathways to induce glioma-like lesions in mice
36. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas
37. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue
38. Human glioblastomas with no alterations of the CDKN2A (p16INKa, MST1) and CDK4 genes have frequent mutations of the retinoblastoma gene
39. Identification of a breast cancer specific gene, BCSG1, by direct differential cDNA sequencing
40. Tissue microarrays for high-throughput molecular profiling of tumor specimens
41. MDM2 and p53 gene expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
42. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
43. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
44. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
45. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin
46. Expression monitoring by hybridization of high-density oligonucleotide arrays
47. Molecular genetic evidence for subtypes of oligoastrocytomas
48. Short alternative splice transcripts of the MDM2 oncogene correlate to malignancy in human astrocytic neoplasms
49. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma.
50. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma
51. Oligondendrogliomas: Incidence and biological behavior in a defined population
52. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2, or Bcl-2 genes
53. Treatment of oligodendroglioma: An update
54. Novel gene transcripts preferentially expressed in human muscles revealed by quantitive hybridization of a high-density cDNA array
55. Alternative reading frames of the INK4a tumor suppressor gene encoding encoding two unrelated proteins capable of inducing cell cycle arrest
56. PTEN gene mutations are seen in high-grade but not low-grade gliomas
57. Molecular pathogenesis of malignant gliomas
58. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
59. Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling
60. cDNA expression array reveals heterogeneous expression profiles in three glioblastoma cell lines
61. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma
62. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
63. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes
64. Cerebral astrocytomas and their derivatives
65. Role of the INK4a locus in tumor suppression and cell motility
66. Radiation therapy in the management of low-grade supratentorial astrocytomas
67. Oligodendrogliomas: The Mayo Clinic experience
68. Grading of oligodendrogliomas
69. Analyzing and comparing nucleic acid sequences by hybridization arrays of oligonucleotides: Evaluation using experimental models
70. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas
71. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
72. PTEN/MMAC mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas
73. Current diagnostic concepts of astrocytic tumors
74. Serial analysis expression
75. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
76. Subsets of glioblastoma multiforme defined by molecular genetic analysis
77. Molecular pathways in the formation of gliomas
78. Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences
79. Overexpression of the EGF-receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
80. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies
81. Role of gemistocytes in astrocytoma progression
82. Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms: A light microscopic and immunohistochemical study of formalin-fixed routinely processed material
83. Structural alterations of the epidermal growth factor receptor in human gliomas
84. A functional p53-responsive intronic promoter is contained within the human MDM2 gene
85. Gene expression profiles in normal and cancer cells